BACKGROUND Dengue virus (DENV) infection is increasingly common in southern China and can be transmitted through blood transfusion but is not currently part of donor screening throughout the region. We assessed DENV prevalence among donors at the Xishuangbanna Blood Center, Yunnan, to support development of DENV screening strategies.
METHODS Blood samples were collected randomly between June 2019 and August 2019. These were screened for anti-DENV IgG and IgM using enzyme-linked immunosorbent assay (ELISA). Then, all reactive samples and some randomly-chosen non-reactive samples were used to detect DENV RNAs using real-time polymerase-chain-reaction (RT-PCR) assays. After RT-PCR, samples were further tested for soluble nonstructural protein 1 (NS1) using the colloidal gold method. Donors demographics were also collected and assessed.
RESULTS Over the study period, 2,254 donor samples were collected and tested for anti-DENV IgG and IgM by ELISA. This revealed 598 anti-DENV IgG and/or IgM reactive samples, a serological prevalence of 26.53%. Of these, 26 were RT-PCR positive and/or NS1 positive. Significant differences in DENV prevalence were noted by occupation (P=0.001), education (P<0.001), and ethnicity (P=0.026).
CONCLUSION The prevalence of DENV in Xishuangbanna Blood Center was higher than most other blood centers that have implemented DENV donor screening. Our study provides first-hand data about the prevalence of DENV and allows the development of a screening strategy for clinical use.

Figure 1
Loading...
Posted 21 Jan, 2021
On 14 Jan, 2021
On 13 Jan, 2021
Posted 11 Jan, 2021
On 11 Jan, 2021
On 10 Jan, 2021
On 06 Jan, 2021
Received 10 Dec, 2020
On 19 Nov, 2020
Invitations sent on 17 Nov, 2020
On 17 Nov, 2020
Received 17 Nov, 2020
On 13 Oct, 2020
On 12 Oct, 2020
On 12 Oct, 2020
On 11 Sep, 2020
Received 10 Sep, 2020
Received 07 Sep, 2020
On 20 Aug, 2020
Invitations sent on 18 Aug, 2020
On 18 Aug, 2020
On 23 Jul, 2020
On 22 Jul, 2020
On 22 Jul, 2020
Posted 21 Jan, 2021
On 14 Jan, 2021
On 13 Jan, 2021
Posted 11 Jan, 2021
On 11 Jan, 2021
On 10 Jan, 2021
On 06 Jan, 2021
Received 10 Dec, 2020
On 19 Nov, 2020
Invitations sent on 17 Nov, 2020
On 17 Nov, 2020
Received 17 Nov, 2020
On 13 Oct, 2020
On 12 Oct, 2020
On 12 Oct, 2020
On 11 Sep, 2020
Received 10 Sep, 2020
Received 07 Sep, 2020
On 20 Aug, 2020
Invitations sent on 18 Aug, 2020
On 18 Aug, 2020
On 23 Jul, 2020
On 22 Jul, 2020
On 22 Jul, 2020
BACKGROUND Dengue virus (DENV) infection is increasingly common in southern China and can be transmitted through blood transfusion but is not currently part of donor screening throughout the region. We assessed DENV prevalence among donors at the Xishuangbanna Blood Center, Yunnan, to support development of DENV screening strategies.
METHODS Blood samples were collected randomly between June 2019 and August 2019. These were screened for anti-DENV IgG and IgM using enzyme-linked immunosorbent assay (ELISA). Then, all reactive samples and some randomly-chosen non-reactive samples were used to detect DENV RNAs using real-time polymerase-chain-reaction (RT-PCR) assays. After RT-PCR, samples were further tested for soluble nonstructural protein 1 (NS1) using the colloidal gold method. Donors demographics were also collected and assessed.
RESULTS Over the study period, 2,254 donor samples were collected and tested for anti-DENV IgG and IgM by ELISA. This revealed 598 anti-DENV IgG and/or IgM reactive samples, a serological prevalence of 26.53%. Of these, 26 were RT-PCR positive and/or NS1 positive. Significant differences in DENV prevalence were noted by occupation (P=0.001), education (P<0.001), and ethnicity (P=0.026).
CONCLUSION The prevalence of DENV in Xishuangbanna Blood Center was higher than most other blood centers that have implemented DENV donor screening. Our study provides first-hand data about the prevalence of DENV and allows the development of a screening strategy for clinical use.

Figure 1
Loading...